Vir Biotechnology (VIR) Enterprise Value (2018 - 2025)
Vir Biotechnology (VIR) has disclosed Enterprise Value for 8 consecutive years, with -$460.9 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 391.75% to -$460.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$460.9 million through Dec 2025, down 391.75% year-over-year, with the annual reading at -$460.9 million for FY2025, 391.75% down from the prior year.
- Enterprise Value hit -$460.9 million in Q4 2025 for Vir Biotechnology, up from -$497.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$18.3 million in Q2 2024 to a low of -$2.3 billion in Q3 2022.
- Historically, Enterprise Value has averaged -$698.8 million across 5 years, with a median of -$531.4 million in 2021.
- Biggest five-year swings in Enterprise Value: surged 98.45% in 2024 and later crashed 1092.39% in 2025.
- Year by year, Enterprise Value stood at -$565.0 million in 2021, then plummeted by 171.54% to -$1.5 billion in 2022, then skyrocketed by 83.61% to -$251.4 million in 2023, then surged by 62.72% to -$93.7 million in 2024, then crashed by 391.75% to -$460.9 million in 2025.
- Business Quant data shows Enterprise Value for VIR at -$460.9 million in Q4 2025, -$497.8 million in Q3 2025, and -$218.4 million in Q2 2025.